TICKERNERD
Menu
RCELRCELHealthcare · Medical Devices

RCEL Stock Forecast: AVITA Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$10
−0.20% on the day

The 3 Wall Street analysts covering AVITA Medical, Inc. hold a median 12-month price target of $11 — +10.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$311.1M
Ticker Nerd rank
63 / 100
Median analyst target
$11
Analysts covering
3
Total return, dividends reinvested
1W
+28.3%
1M
+97.8%
YTD
+191.9%
1Y
+112.0%
From 52W high
−2.6%
From 52W low
+208.0%
$3
$10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RCEL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AVITA Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Revisions
87
Growth
62
Size
62
Momentum
59
Value
43
Quality
39
Issuance
14
Volatility
13

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RCEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RCEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26RCELHigh $14Median $11Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $8Median $11High $14

The green dot is the last close — the median target sits +10.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Aug 2026BTIGMaintainsBuy$7.00 → $11
19 Aug 2026TD CowenMaintainsBuy$12 → $14
7 Aug 2026BTIGUpgradeBuy—
7 Aug 2026BTIGUpgradeBuy$7.00
15 May 2026Lake StreetUpgradeBuy—
15 May 2026Lake StreetUpgradeBuy$3.50 → $6.00
9 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
5 Mar 2026Northland Capital MarketsInitiatesOutperform—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026D. Boral CapitalMaintainsBuy—
16 Jan 2026Lake StreetMaintainsHold—
15 Jan 2026D. Boral CapitalMaintainsBuy—
20 Nov 2025BTIGUpgradeNeutral—
7 Nov 2025D. Boral CapitalMaintainsBuy—
17 Oct 2025D. Boral CapitalMaintainsBuy—
17 Oct 2025Lake StreetDowngradeHold—
15 Sept 2025D. Boral CapitalMaintainsBuy—
5 Sept 2025D. Boral CapitalMaintainsBuy—
11 Aug 2025Lake StreetMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCEL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RCEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

AVITA Medical, Inc. (RCEL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 90% of US stocks

Price / sales
4.1×

Cheaper than 31% of US stocks

Price / book
−11.1×

Cheaper than 98% of US stocks

EV / EBITDA
−10.6×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
17.8%

Higher than 67% of US stocks

Earnings growth (YoY)
17.8%

Higher than 57% of US stocks

Gross margin
81.9%

Higher than 92% of US stocks

Operating margin
−31.6%

Higher than 19% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
291.8%

Higher than 99% of US stocks

Return on assets
−41.6%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RCEL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
RCELAVITA Medical, Inc.$311.1M
63
CVCapsoVision, Inc.$300.0M
20
TLSITriSalus Life Sciences, Inc.$315.2M
29
ELMDElectromed, Inc.$329.0M
99
VMDViemed Healthcare, Inc.$336.5M
96
TMCITreace Medical Concepts, Inc.$276.5M
55
MOBIMobia Medical, Inc.$351.0M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AVITA Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RCEL news & analysis

Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft

MarketBeat · 19 Aug 2026positive

Avita Medical presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. The headline reports a 70% cost reduction with PermeaDerm versus allograft.

Why it matters — The study results highlight a potential cost advantage of PermeaDerm over cadaveric allograft, which could be relevant to the company's wound coverage product.

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

Seeking Alpha · 19 Aug 2026neutral

Seeking Alpha published the transcript of AVITA Medical, Inc.'s (RCEL) shareholder/analyst call. The excerpt provides no specific details from the call beyond the fact that the transcript was released.

Why it matters — RCEL watchers can use the call transcript to review management's latest commentary and disclosures directly from the company.

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

GlobeNewsWire · 18 Aug 2026positive

AVITA Medical announced positive study results for its PermeaDerm product, showing a 70% lower product cost than allograft with comparable clinical outcomes and a 96% reduction in preparation time.

Why it matters — The results highlight a potential economic and efficiency advantage for PermeaDerm, which could be significant for AVITA Medical's product portfolio.

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

MarketBeat · 16 Aug 2026positive

Avita Medical reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from the first quarter and 18% year over year, attributing the increase to growth across its product portfolio and in U.S. and international markets. The company raised its 2026 revenue outlook.

Why it matters — A RCEL watcher would care because the company's accelerating revenue growth and raised 2026 outlook signal strengthening business performance in both domestic and international markets.

Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds

MarketBeat · 16 Aug 2026positive

Avita Medical President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference that the company expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025.

Why it matters — RCEL watchers would care because the statement outlines the company's near-term revenue growth expectations and its target timeline for reaching cash flow breakeven.

FAQ

Frequently asked questions about RCEL stock

What is the RCEL stock price forecast for 2026-2027?

The 3 Wall Street analysts covering AVITA Medical, Inc. have a median 12-month price target of $11, with estimates ranging from $8.16 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RCEL stock a buy right now?

Of the 3 analysts covering AVITA Medical, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AVITA Medical, Inc. 63 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RCEL?

As at 22 Aug 2026, AVITA Medical, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

Will RCEL stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +10.5% from the last close, and Ticker Nerd's factor model ranks AVITA Medical, Inc. 63 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RCEL stock forecast for 2030?

No analyst covering AVITA Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.16 to $14 over the next 12 months.

How has RCEL stock performed over the past year?

AVITA Medical, Inc. returned +112.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AVITA Medical, Inc. do?

Avita Medical Inc. is a global regenerative medicine company that focuses on harnessing the body's innate regenerative ability to address significant unmet medical needs in the field of burns, chronic wounds, and skin rejuvenation therapies.

What is the latest news on RCEL?

The most recent item we track (MarketBeat, 19 Aug 2026): "Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft". Avita Medical presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft. The headline reports a 70% cost reduction with PermeaDerm versus allograft.

Company

About AVITA Medical, Inc.

Avita Medical Inc. is a global regenerative medicine company that focuses on harnessing the body's innate regenerative ability to address significant unmet medical needs in the field of burns, chronic wounds, and skin rejuvenation therapies. The company's core product is the RECELL System, an innovative approach designed to enhance the healing of skin ailments and injuries by using a patient's own skin cells. This system stands out for its ability to significantly reduce the need for extensive skin grafting, which is traditionally required in burn treatment, thereby minimizing donor site morbidity and improving patient outcomes. Avita Medical is particularly influential in the healthcare and biotechnology sectors, providing a crucial solution for patients and medical practitioners dealing with burn treatment and epithelial resurfacing procedures. Its technology holds the potential to revolutionize standard care practices due to its minimally invasive application and efficient healing outcomes. With international recognition, the company plays a vital role in advancing the field of regenerative medicine, offering hope through innovations that enhance quality of life for patients with serious skin injuries and conditions.

CEO Mr. Cary G. Vance · 226 employees · United States · https://avitamedical.com